Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
2023 CMTA Annual Report
…committed to our mission of supporting the development of new treatments for CMT, improving the quality of life for those with CMT, and ultimately finding a cure. Your support, passion,…
CMTA 2023 Annual Report Download
…effective treatments to patients. The new projects approved in 2023 cover both axonal and demyelinating types of CMT, including treatment approaches applicable to multiple types, showcasing CMTA’s commitment to comprehensive…
2023 CMTA Annual Report
…in developing and commercializing treatments for rare diseases, Sue’s leadership marks a pivotal moment in our journey towards finding a cure for CMT. Sue brings a wealth of expertise to…
STAR_Webinar_Transcript
…with CMT. Nevertheless, for people like you and for me, 10 years feels like an eternity when there are still no viable treatments for CMT. On the other hand, 10…
NeuroMeds
…placement of some agents. As with any treatment, the risk of neuropathy exacerbation must be weighed against expected treatment benefits and available equivalent, alternative treatments. Despite the limitations of this…
Managing_Neuropathic_Pain_Dr_Steven_Scherer
…calcium channel a2-d ligands (i.e., gabapentin and pregabalin), and topical lidocaine” were considered first-line treatments, with opioids as “generally second-line treatments”. “Third-line treatments that could also be used as second-line…
2022 Annual Report_spreads
…leading academic labs, clinical centers and pharmaceutical and biotech companies to advance scientific knowledge, increase clinical trial readiness and accelerate progress towards treatments for CMT. Today, CMTA-STAR is the largest…
CMT Respiratory Impairment Article_Kenny and Ashraf_Updated 2022
…are basically oxygen as needed, an inhaler or two, and nebulizer treatments. Oxygen is used to treat hypoxemia/hypoxia, and inhalers/nebulizer treatments are used to open the airways and to prevent…
2017_Fall_CMTA_Report
…may use to aid and supplement a doctor’s treatment. CMTA LEADERSHIP CMTA STAFF Amy J. Gray, CEO BOARD OF DIRECTORS Gilles Bouchard, Chairman Gary Gasper, Treasurer Herb Beron, Secretary Thomas…
2017_Fall_CMTA_Report
…may use to aid and supplement a doctor’s treatment. CMTA LEADERSHIP CMTA STAFF Amy J. Gray, CEO BOARD OF DIRECTORS Gilles Bouchard, Chairman Gary Gasper, Treasurer Herb Beron, Secretary Thomas…